Abstract: The present disclosure provides a kit for detecting an anti-vinculin-immunoglobulin G (IgG) antibody, including the antigen protein vinculin, a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color development reagent, a washing solution, a standard, a positive quality control, and negative quality control. In the present disclosure, the kit can detect the anti-Vinculin-IgG antibody in a sample to be tested by indirect reaction combined with magnetic particle-based chemiluminescence immunoassay. Autoantibodies against the target antigen vinculin are identified in the serum of a patient with autoimmune nephrotic syndrome for the first time, and a detection kit is provided for the autoantibodies. The present disclosure provides a basis for molecular mechanism research and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to vinculin and vinculin-IgG autoantibodies at home and abroad.

Abstract: The present disclosure provides a kit for detecting an anti-proteasome subunit alpha type 1-immunoglobulin G (IgG) antibody, including an antigen protein proteasome subunit alpha type 1, a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color development reagent, a washing solution, a standard, a positive quality control, and a negative quality control. In the present disclosure, the kit is capable of detecting the anti-proteasome subunit alpha type 1-IgG antibody in serum to be tested by indirect reaction combined with magnetic particle-based chemiluminescence immunoassay. Autoantibodies against the target antigen protein proteasome subunit alpha type 1 are identified in the serum of a patient with autoimmune nephrotic syndrome for the first time.